Stock 4013 DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dr. Sulaiman Al Habib Medical Services Group Company

Equities

4013

SA1510P1UMH1

Healthcare Facilities & Services

Market Closed - Saudi Arabian S.E.
Other stock markets
 08:20:05 2024-05-30 am EDT 		5-day change 1st Jan Change
268.2 SAR -2.97% Intraday chart for Dr. Sulaiman Al Habib Medical Services Group Company -5.56% -5.56%
May. 19 Dr. Sulaiman Al Habib Medical Services Declares Q1 Dividend MT
May. 19 Dr. Sulaiman Al Habib Medical Services Group Company Announces Cash Dividend for First Quarter of the Fiscal Year 2024, Payable on June 10, 2024 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 38,150 56,490 77,210 99,400 93,870 - -
Enterprise Value (EV) 1 38,150 56,609 77,663 101,963 99,713 99,786 100,986
P/E ratio 36.1 x 41.1 x 46.7 x 48.5 x 42.5 x 35 x 29.2 x
Yield 1.38% 1.67% - - 1.63% 1.85% 2.1%
Capitalization / Revenue 6.51 x 7.79 x 9.29 x 10.5 x 8.28 x 6.5 x 5.86 x
EV / Revenue 6.51 x 7.81 x 9.34 x 10.7 x 8.8 x 6.91 x 6.31 x
EV / EBITDA 26.6 x 31.8 x 38.6 x 42.3 x 34 x 27.8 x 23.7 x
EV / FCF 26.9 x 60.9 x 58.4 x -403 x -131 x 58 x 40.2 x
FCF Yield 3.72% 1.64% 1.71% -0.25% -0.77% 1.72% 2.49%
Price to Book 7.77 x 10.6 x 13.1 x 15.3 x 12.9 x 11.7 x 9.99 x
Nbr of stocks (in thousands) 350,000 350,000 350,000 350,000 350,000 - -
Reference price 2 109.0 161.4 220.6 284.0 268.2 268.2 268.2
Announcement Date 2/21/21 2/20/22 2/21/23 2/20/24 - - -
1SAR in Million2SAR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,862 7,250 8,311 9,508 11,334 14,443 16,013
EBITDA 1 1,433 1,781 2,010 2,408 2,934 3,591 4,260
EBIT 1 1,115 1,466 1,700 2,096 2,316 2,926 3,491
Operating Margin 19.02% 20.22% 20.46% 22.04% 20.44% 20.26% 21.8%
Earnings before Tax (EBT) 1 1,128 1,491 1,797 2,170 2,384 2,930 3,609
Net income 1 1,055 1,377 1,651 2,046 2,201 2,731 3,238
Net margin 18.01% 18.99% 19.86% 21.52% 19.42% 18.91% 20.22%
EPS 2 3.020 3.930 4.720 5.850 6.310 7.658 9.175
Free Cash Flow 1 1,420 929.3 1,330 -252.7 -763.3 1,720 2,510
FCF margin 24.23% 12.82% 16.01% -2.66% -6.73% 11.91% 15.68%
FCF Conversion (EBITDA) 99.14% 52.18% 66.19% - - 47.9% 58.93%
FCF Conversion (Net income) 134.57% 67.5% 80.59% - - 63% 77.53%
Dividend per Share 2 1.500 2.700 - - 4.372 4.970 5.624
Announcement Date 2/21/21 2/20/22 2/21/23 2/20/24 - - -
1SAR in Million2SAR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1
Net sales 1 1,968 1,991 2,014 2,052 2,254 2,307 2,272 2,443 2,486 2,521
EBITDA - 498.7 - - 505.3 - 577 - - -
EBIT 1 396.3 422.1 414.7 436.1 427.6 510.6 498.8 552.1 534.2 556.1
Operating Margin 20.13% 21.2% 20.59% 21.25% 18.97% 22.13% 21.95% 22.6% 21.48% 22.05%
Earnings before Tax (EBT) - - - - - - - - - -
Net income 1 383.6 390.5 398.1 420.6 441.5 489.3 487 544.8 491 551
Net margin 19.49% 19.61% 19.77% 20.5% 19.59% 21.21% 21.43% 22.3% 19.75% 21.85%
EPS 2 1.090 - - 1.200 1.260 1.400 1.390 1.560 1.500 1.570
Dividend per Share - - - - - - - - - -
Announcement Date 2/20/22 4/24/22 8/7/22 10/23/22 2/21/23 5/7/23 8/6/23 10/30/23 2/20/24 4/28/24
1SAR in Million2SAR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 119 453 2,563 5,843 5,916 7,116
Net Cash position 1 - - - - - - -
Leverage (Debt/EBITDA) - 0.0667 x 0.2255 x 1.064 x 1.991 x 1.647 x 1.67 x
Free Cash Flow 1 1,420 929 1,330 -253 -763 1,720 2,510
ROE (net income / shareholders' equity) 22.7% 26.9% 29.4% 33.1% 31.9% 35.1% 36.6%
ROA (Net income/ Total Assets) 11.8% 13.6% 14.1% 14.4% 13% 14.8% 15.3%
Assets 1 8,974 10,154 11,706 14,191 16,927 18,430 21,210
Book Value Per Share 2 14.00 15.30 16.80 18.50 20.80 22.80 26.90
Cash Flow per Share 2 - - - 9.270 7.200 8.700 11.10
Capex 1 758 1,254 1,513 3,497 3,472 2,148 1,798
Capex / Sales 12.93% 17.29% 18.21% 36.78% 30.64% 14.87% 11.23%
Announcement Date 2/21/21 2/20/22 2/21/23 2/20/24 - - -
1SAR in Million2SAR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Dr. Sulaiman Al Habib Medical Services Group Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
268.2 SAR
Average target price
287.1 SAR
Spread / Average Target
+7.05%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
-5.56% 25.03B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+25.52% 88.99B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-24.52% 74.82B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
+4.31% 17.88B
LABCORP HOLDINGS INC. Stock Labcorp Holdings Inc.
-14.25% 16.43B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
+2.97% 15.77B
NATERA, INC. Stock Natera, Inc.
+70.11% 13.09B
TENET HEALTHCARE CORPORATION Stock Tenet Healthcare Corporation
+79.20% 13.21B
DAVITA INC. Stock DaVita Inc.
+40.44% 12.9B
UNIVERSAL HEALTH SERVICES, INC. Stock Universal Health Services, Inc.
+24.51% 12.7B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. 4013 Stock
  4. Financials Dr. Sulaiman Al Habib Medical Services Group Company